mai President Prapan Charoenprawatt said that WINMED would list and start trading on mai in the Consumer Products industry group.
WINMED is an importer and distributor of analytical, diagnostic and/or remedial medical supplies and equipment, including medical supplies and devices related to blood collection and blood-related products. WINMED has been appointed as the importer and distributor for medical and diagnostic productsfrom 23 manufacturers in 12 countries, while being exclusive distributor for leading manufacturers worldwide such as Germany, USA and Spain, etc. In addition, the company is also a representative of overseas genetics diagnostic service providers for genetic material testing and fetal abnormalities. Moreover, WINMED also has a subsidiary that distributes health & hygiene-oriented scientific and technological products. In 2020, WINMED's medical and healthcare clients consisted of government agencies and laboratories (63 percent); hospitals and private medical clinics and labs (26 percent); and social welfare organizations such as National Blood Center, the Thai Red Cross Society (11 percent).
WINMED has a registered paid-up capital of THB 200 million, consisting of 280 million existing common shares and 120 million newly issued shares, with a par value of THB 0.50 each. It offered up to 90 million newly issued shares to persons under the underwriter's discretion, up to 18 million newly issued shares to the company's patrons, up to 12 million newly issued shares to directors, executives, and/or employees of WINMED and its subsidiary on April 30 and during May 5 - 6 at THB 3.10 each, for a total of THB 372 million. The IPO price is equivalent to the price-to-earnings ratio (P/E ratio) of 24.04 times. The earnings per share is equal to THB 0.129, calculated from the company's net profit of THB 51.59 million in the past 12 months (from January 1 to December 31, 2020), divided by fully diluted shares. Asset Pro Management Co., Ltd. is its financial advisor and Finansia Syrus Securities pcl is the lead underwriter.
WINMED Chief Executive Officer Nanthiya Darakananda said that WINMED has had over 24 years of experience and expertise in medical supply import and distribution business, being appointed as exclusive distributorsfor leading world-class medical manufacturers. The company is committed to enhancing healthcare and quality of life by allocating the best-in-class medical technologies from various sources worldwide. The fundraising will be used to build a cell culture laboratory for cell therapy treatment, invest in the construction of an HPV testing laboratory, repay loans, and as working capital.
WINMED's three major shareholders after the IPO are Sumeth Darakananda Family Group (60.43 percent), Jinhatha Panyasorn (9.74 percent), and Pinijporn Darakananda Kasemsub (0.91 percent). The company's and subsidiary's dividend policy are to pay no less than 40 percent of net profit after legal reserves and other reserves as specified by each company.
For more information on WINMED, please see the company's prospectus at the Securities and Exchange Commission's website at www.sec.or.th ; and for general information, please visit www.winnergymedical.co.th and www.set.or.th.
Source: SET